Alkermes (ALKS) Other Non-Current Liabilities (2011 - 2026)
Alkermes' (ALKS) quarterly Other Non-Current Liabilities came in at $109.5 million in Q1 2026, up 86.05% year-on-year from $58.9 million in Q1 2025, and up 92.93% on a QoQ basis from $56.8 million in Q3 2025.
Alkermes (ALKS) Other Non-Current Liabilities (2011 - 2026) Analysis & Trends
Alkermes (ALKS) has 16 years of Other Non-Current Liabilities data on file, last reported at $109.5 million in Q1 2026.
- On a quarterly basis, Other Non-Current Liabilities rose 86.05% year-over-year to $109.5 million in Q1 2026; TTM through Mar 2026 was $109.5 million, a 86.05% increase from a year earlier, with the FY2024 full-year figure at $56.0 million, up 12.31% from the prior year.
- Other Non-Current Liabilities for Q1 2026 stood at $109.5 million, up from $56.8 million in the prior quarter.
- Over the last five years, Other Non-Current Liabilities for ALKS reached as high as $109.5 million in Q1 2026 and fell as low as $42.4 million in Q4 2022.
- Historically, Other Non-Current Liabilities has averaged $53.9 million across 5 years, with a median of $49.4 million in 2023.
- Across the five-year window, Other Non-Current Liabilities fell 2.9% in 2022 and jumped 86.05% in 2026, its largest moves.
- Year by year, Other Non-Current Liabilities stood at $42.4 million in 2022, then advanced by 17.68% to $49.9 million in 2023, then advanced by 12.31% to $56.0 million in 2024, then gained by 1.31% to $56.8 million in 2025, then jumped by 92.93% to $109.5 million in 2026.
- Per Business Quant data, the three most recent Other Non-Current Liabilities figures were $109.5 million in Q1 2026, $56.8 million in Q3 2025, and $56.0 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Alkermes | 9.72 Bn | 9.21 Bn | 331.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 109.49 Mn |
| Sep 30, 2025 | 56.75 Mn |
| Jun 30, 2025 | 56.05 Mn |
| Mar 31, 2025 | 58.85 Mn |
| Dec 31, 2024 | 56.02 Mn |
| Sep 30, 2024 | 52.63 Mn |
| Jun 30, 2024 | 48.29 Mn |
| Mar 31, 2024 | 48.96 Mn |
| Dec 31, 2023 | 49.88 Mn |
| Sep 30, 2023 | 53.62 Mn |
| Jun 30, 2023 | 48.22 Mn |
| Mar 31, 2023 | 48.49 Mn |
| Dec 31, 2022 | 42.38 Mn |
| Sep 30, 2022 | 42.86 Mn |
| Jun 30, 2022 | 45.21 Mn |
| Mar 31, 2022 | 43.91 Mn |
| Dec 31, 2021 | 43.65 Mn |
| Sep 30, 2021 | 32.12 Mn |
| Jun 30, 2021 | 36.32 Mn |
| Mar 31, 2021 | 36.27 Mn |